bibh 1
mAbexperimentalADC
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 1998 (NCT02199886)
Timeline
Indications
Mechanism of action
- Fibroblast activation protein alphaBINDING AGENT
FAP binding agent
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109643 ↗
Also known as
- bibh 1
- bibh-1
- f19
- f19
- f19
- f19 131i
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02198274 | Phase 2 | Feb 1, 2000 | Boehringer Ingelheim |
| NCT00005616 | Phase 1 | Sep 1, 1999 | Cornell University, National Cancer Institute (NCI) |
| NCT00004042 | Phase 1 | Nov 1, 1998 | Cornell University, National Cancer Institute (NCI) |
| NCT02199886 | Phase 1 | Jul 1, 1998 | Boehringer Ingelheim |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 2 | 2 | 2 | 1998 |
| Cornell University | Academic/Hospital | 2 | 2 | 1 | 1998 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 1998 |
3 organizations
Page 1 / 1